102-LB: Cumulative Probability of Mortality among Non-Hispanic Black Compared with Non-Hispanic White Individuals with Type 2 Diabetes on Empagliflozin (EMPA-AA)—Real-World Data

Authors 1, 2 & 11 participated equally. Given the underrepresentation of minorities in the CV outcome trials, guidelines encouraged investigating antihyperglycemic medications in minorities, particularly in non-Hispanic Blacks (Black). Our goal was to evaluate the incidence of all-cause mortality (ACM) among Black vs non-Hispanic White (White) patients with type 2 diabetes (T2D) who were prescribed empagliflozin (EMPA). We performed a multicenter retrospective study using EMR-derived data for adults with T2D cared for at 4 healthcare systems in North and South Carolina between Aug 2014 and Dec 2019. In patients without HF hospitalizations (hHF) prior to an initial EMPA prescription, we compared ACM in Black vs White patients. A propensity-score weighted analysis was performed to balance characteristics by race. The cumulative probability of ACM by race was estimated using the cumulative incidence function. A total of 8789 patients were eligible. Baseline characteristics and results are summarized in Table 1. After propensity-score weighted analysis adjusting for age, gender, and baseline comorbidities, there was no significant difference in the risk of ACM between Black vs White patients. In patients with T2D without hHF prior to an initial EMPA prescription, we found no significant difference in ACM in Black vs White patients. Disclosure B. M. Mishriky: Advisory Panel; Bayer Inc., Research Support; Lilly. A. Adams: None. W. Irish: Consultant; Eurofins Transplant Genomics, Other Relationship; CTI Clinical Trial and Consulting. D. M. Cummings: None. Y. Fu: None. J. Halladay: None. W. S. Jones: None. A. D. Boan: None. S. Jones berkeley: None. S. P. Patil: None. J. R. Powell: None. Funding Brody Brothers Endowment Fund (20-0922)